Perceptive Advisors - 4D MOLECULAR THERAPEUTICS IN ownership

4D MOLECULAR THERAPEUTICS IN's ticker is FDMT and the CUSIP is 35104E100. A total of 112 filers reported holding 4D MOLECULAR THERAPEUTICS IN in Q3 2023. The put-call ratio across all filers is 0.97 and the average weighting 0.1%.

Quarter-by-quarter ownership
Perceptive Advisors ownership history of 4D MOLECULAR THERAPEUTICS IN
ValueSharesWeighting
Q3 2021$10,121,000
-44.0%
375,256
-50.0%
0.15%
+25.6%
Q2 2021$18,072,000
-6.4%
750,512
+68.7%
0.12%
-52.0%
Q1 2021$19,298,000
-22.4%
444,878
-25.9%
0.24%
-8.6%
Q4 2020$24,881,000600,2560.27%
Other shareholders
4D MOLECULAR THERAPEUTICS IN shareholders Q3 2023
NameSharesValueWeighting ↓
BVF INC/IL 4,007,413$68,887,4292.52%
Opaleye Management Inc. 314,000$5,397,6601.62%
Deep Track Capital, LP 2,278,107$39,160,6591.61%
Casdin Capital, LLC 1,070,000$18,393,3001.52%
Eagle Health Investments LP 437,911$7,527,6901.46%
ACUTA CAPITAL PARTNERS, LLC 104,753$1,800,7041.33%
Octagon Capital Advisors LP 499,996$8,594,9311.24%
Soleus Capital Management, L.P. 469,400$8,068,9860.84%
Novo Holdings A/S 700,000$12,033,0000.79%
VIKING GLOBAL INVESTORS LP 3,937,914$67,692,7420.32%
View complete list of 4D MOLECULAR THERAPEUTICS IN shareholders